文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

巴雷特食管高级别异型增生患者的监测和随访策略:一项荷兰基于人群的研究。

Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.

机构信息

Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.

出版信息

Am J Gastroenterol. 2012 Apr;107(4):534-42. doi: 10.1038/ajg.2011.459. Epub 2012 Jan 24.


DOI:10.1038/ajg.2011.459
PMID:22270082
Abstract

OBJECTIVES: In patients with high-grade dysplasia (HGD) in Barrett's esophagus (BE), it is incompletely known which factors are associated with developing esophageal adenocarcinoma (EAC). We analyzed prior biopsy and follow-up strategies in a large nationwide population-based cohort of patients with HGD in BE, and identified predictors of EAC progression. METHODS: Prior biopsy records and follow-up evaluations were studied in patients with HGD in BE diagnosed between 1999 and 2008, using PALGA, a nationwide network and registry of histopathology and cytopathology in the Netherlands. Multivariate Cox proportional hazards regression analysis was performed to identify predictors for prevalent (≤ 6 months) and incident (> 6 months) EAC. RESULTS: In total, 827 patients with HGD in BE were included. Follow-up data after HGD diagnosis were available in 699 (85%) patients. In 249 (36%) of these patients, an EAC was detected (14.1 EACs per 100 person-years). The risk of prevalent EAC (n=177) was lower with previous surveillance (hazards ratio 0.7; 95% confidence interval 0.5-0.9), unifocal HGD (0.3;0.2-0.6), diagnosis in a university hospital (0.5;0.3-0.9), endoscopic resection (0.5;0.3-0.7), or ablation (0.0;0.0-0.3); and higher when patients were 65-75 years (1.5;1.04-2.04). After exclusion of prevalent EACs, the progression rate was 4.2 EACs per 100 person-years. The risk of progression to incident EAC (n = 72) was lower with previous surveillance (0.6;0.3-0.9) and ablation (0.2;0.0-0.8), and higher when > 75 years (3.8;2.0-7.2) or with an interval > 6 months between HGD diagnosis and first follow-up (e.g., 7-12 months 2.9;1.3-6.3). CONCLUSIONS: In this cohort of patients with HGD in BE, the EAC detection rate was 14.1 per 100 person-years and 4.2 per 100 person-years after excluding prevalent cases. The risk of both prevalent and incident EAC was reduced with previous surveillance and endoscopic treatment, while it was increased with older age.

摘要

目的:在 Barrett 食管(BE)中出现高级别异型增生(HGD)的患者中,尚不完全清楚哪些因素与食管腺癌(EAC)的发展相关。我们分析了大量 BE 中 HGD 患者的既往活检和随访策略,并确定了 EAC 进展的预测因素。

方法:通过荷兰全国性的组织病理学和细胞病理学网络和登记处 PALGA,研究了 1999 年至 2008 年间诊断为 BE 中 HGD 的患者的既往活检记录和随访评估。使用多变量 Cox 比例风险回归分析来确定 EAC 进展的预测因素(随访 6 个月内出现的 EAC 为现患性,随访 6 个月以上出现的 EAC 为新发性)。

结果:共纳入 827 例 BE 中 HGD 患者。在 699 例(85%)患者中可获得 HGD 诊断后的随访数据。在这些患者中,有 249 例(36%)检测到 EAC(每 100 人年 14.1 例)。现患性 EAC(n=177)的风险较低与先前的监测(风险比 0.7;95%置信区间 0.5-0.9)、单灶性 HGD(0.3;0.2-0.6)、在大学医院诊断(0.5;0.3-0.9)、内镜切除(0.5;0.3-0.7)或消融(0.0;0.0-0.3)有关;而患者年龄在 65-75 岁时风险较高(1.5;1.04-2.04)。排除现患性 EAC 后,进展率为每 100 人年 4.2 例。新发 EAC(n=72)进展的风险较低与先前的监测(0.6;0.3-0.9)和消融(0.2;0.0-0.8)有关,而年龄较高(>75 岁)或 HGD 诊断与首次随访之间的间隔较长(如 7-12 个月,2.9;1.3-6.3)时风险较高。

结论:在本队列中,BE 中 HGD 患者的 EAC 检出率为每 100 人年 14.1 例,排除现患性病例后为每 100 人年 4.2 例。现患性和新发性 EAC 的风险均随先前的监测和内镜治疗而降低,而随年龄增长而增加。

相似文献

[1]
Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.

Am J Gastroenterol. 2012-1-24

[2]
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Am J Gastroenterol. 2011-5-17

[3]
Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.

Endoscopy. 2014-12-18

[4]
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.

Gastroenterology. 2011-6-30

[5]
Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).

Ann Surg. 2012-11

[6]
Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.

Dis Esophagus. 2017-3-1

[7]
Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Am J Gastroenterol. 1999-12

[8]
Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.

Am J Gastroenterol. 2005-4

[9]
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Am J Gastroenterol. 2009-11

[10]
Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.

Clin Gastroenterol Hepatol. 2006-5

引用本文的文献

[1]
Reflux, Barrett's Esophagus, and Esophageal Adenocarcinoma After Bariatric Surgery.

Foregut. 2021-12

[2]
RISK OF PRENEOPLASTIC LESIONS IN MUCOSAL PROJECTIONS OF DIFFERENT SIZES OF THE COLUMNAR EPITHELIUM IN THE LOWER ESOPHAGUS.

Arq Bras Cir Dig. 2022

[3]
Salvage cryotherapy in patients undergoing endoscopic eradication therapy for complicated Barrett's esophagus.

Endosc Int Open. 2019-7

[4]
Role of endoscopy in early oesophageal cancer.

Nat Rev Gastroenterol Hepatol. 2016-11-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索